Analysts have been eager to weigh in on the Healthcare sector with new ratings on Shattuck Labs (STTK – Research Report), Johnson & Johnson (JNJ – Research Report) and Tilray (TLRY – Research Report).
Shattuck Labs (STTK)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Shattuck Labs, with a price target of $28.00. The company’s shares closed last Wednesday at $9.45.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Shattuck Labs has an analyst consensus of Strong Buy, with a price target consensus of $17.33, a 94.7% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $12.00 price target.
See the top stocks recommended by analysts >>
Tilray (TLRY)
CIBC analyst John Zamparo maintained a Hold rating on Tilray today and set a price target of $2.00. The company’s shares closed last Wednesday at $2.04.
According to TipRanks.com, Zamparo is ranked #6170 out of 8799 analysts.
Currently, the analyst consensus on Tilray is a Hold with an average price target of $2.30, which is a 16.8% upside from current levels. In a report issued on April 5, Alliance Global Partners also maintained a Hold rating on the stock with a $2.75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STTK:
- Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
- Shattuck Labs Boosts Board with Biotech Heavyweights
- Shattuck Labs appoints Siegall, Sasser to board of directors
- Shattuck Labs reports Q4 EPS (41c), consensus (57c)
